376 Victoria Avenue, Suite 220
41 articles with Knight Therapeutics
Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA ® (estradiol and progesterone) capsules by Health Canada. In Canada, BIJUVA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women wi
Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY ®
Knight Therapeutics Inc., a pan-American specialty pharmaceutical company and Debiopharm, a Swiss-based, global biopharmaceutical company, announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® in Canada.
Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for BIJUVA® has been accepted for review by Health Canada. BIJUVA, estradiol and progesterone capsules, is licensed by Knight from TherapeuticsMD
Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), today announced they have entered into a Distribution, License and Supply Agreement with Knight Therapeutics Inc. (“Knight”),
Knight Therapeutics Inc. and TherapeuticsMD, Inc. announced today that Knight's New Drug Submission for Joyesta™ has been accepted for review by Health Canada.
Medison Urges Knight Therapeutics and Jonathan Goodman to Aggressively Pursue Opportunities Created by Distressed Opioid Case Targets
Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.5% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), today commented on the recent claims brought against various pharma companies in the United States and Canada (including against Joddes and Pharmascience, the Goodman family businesses in which Jonathan Goodman, Knight’s CEO, personally owns at least a 25% interest).
Israeli Courts Rule Against Knight Therapeutics’ and Jonathan Goodman in Frivolous and Costly Litigation Aimed at Silencing Medison
Medison calls on Knight board of directors and shareholders to demand Goodman nominate someone other than himself to the Medison board to ensure their interests are properly represented
Medison Biotech Considers Requisition of Special Meeting of Shareholders of Knight Therapeutics Inc.
Medison Biotech (1995) Ltd. and its affiliates own or control more than 10.4 million shares of Knight Therapeutics Inc., representing approximately 7.3% of the total issued shares of the Company.
Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer
Puma Biotechnology, Inc. announced that its licensing partner Knight Therapeutics Inc. has received marketing authorization from Health Canada to commercialize NERLYNX® in Canada for the extended adjuvant treatment of women with early stage hormone receptor positive, HER2-overexpressed/amplified breast cancer within one year after completion of trastuzumab-based adjuvant therapy.
Medison Biotech: Jonathan Goodman Takes Advantage of His Own Failure to Create Value, Enriching Himself at the Expense of the Shareholders of Knight Therapeutics
NCIB introduced by Knight proposes to buy back shares from shareholders at a 25% discount compared to last capital raise in 2016 of $10 per share
Medison Issues Open Letter to Knight Therapeutics Shareholders Urging Jonathan Goodman to Build Real Business during the Grace Period Knight Received
Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (“Knight” or the “Company”), today issued the following open letter from Medison CEO Meir Jakobsohn on Knight’s continued underperformance and conflicts of interest:
Medimetriks Pharmaceuticals Focuses on Advancing MM36 (difamilast) Through Phase 3 Trials; Extinguishes Debt Owed to Knight Therapeutics
Medimetriks Pharmaceuticals, Inc. announced that the Company is in discussions for various financing options to advance MM36 (difamilast) through phase 3 pivotal trials and potential FDA approval.
Medison Urges Fellow Shareholders to Bring Positive Change to Knight Therapeutics by Voting for All Six of Medison's Highly Qualified Nominees at Upcoming Annual Meeting
Failures at Knight have been exposed by multiple, independent third parties
ISS Notes "Stark" Underperformance, Recommends Election of New Independent Directors and for Knight Shareholders to Vote on the GOLD Proxy Card
Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) ("Knight" or the "Company"), today made its case for urgent change, improved governance and a promising future at the Company in a detailed presentation to shareholders.
Leading Canadian Corporate Governance Expert Confirms Acute Board Conflicts and Governance Deficiencies at Knight Therapeutics
Report includes 54 recommended governance improvements for Knight and is available to all investors
Medison Issues Letter to Shareholders of Knight Therapeutics, Outlining Qualified, Independent Director Nominees and Common-Sense Plan to Build Value
Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc.
Medison Disappointed that Knight Therapeutics has Resorted to Blatant Misrepresentations to Avoid Scrutiny
Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX: GUD) ("Knight" or the "Company"), today responded to Knight's continuing campaign of misinformation and hypocrisy.
Knight Therapeutics and Triumvira Immunologics Triumphantly Announce Secured Bridge Loan & License Agreement
Knight Therapeutics Inc. announced it has entered into a secured loan and exclusive License Agreement with privately-held Triumvira Immunologics Inc.